{"data":{"issuanceinfo":{"industrycode":"204005","industry":"醫療保健","ipoprice":{"ceiling":"12.800","floor":"11.100"},"ipodate":{"start":"2019-02-14 00:00:00","end":"2019-02-19 00:00:00"},"minimumcapital":"6464.49","subscribed":"7.20","marketcap":"118.09億","H_marketcap":"--","pe":"--","codesrate":"100.00","link":"https://staticpdf.iqdii.com/stockdata/notice/Prospectus/02616/LTN20190214042_C.pdf","ipopricing":"12.000","resultdate":"2019-02-25 00:00:00","enddate":"2019-02-19 00:00:00","listeddate":"2019-02-26 00:00:00","issuenumber":"18639.60萬","issuenumberhK":"1864.00萬","issuenumberother":"16775.60萬","grayprice":"13.00","sponsors":"高盛(亞洲)有限責任公司,摩根士丹利亞洲有限公司","raisemoney":"207389.00萬","use":"1、預計約622.17百萬港元（相當于所得款項凈額的30.0%）將分配至以下我們 的核心候選產品；\n2、預計約829.56百萬港元（相當于所得款項凈額的40.0%）將分配至以下管線 中其余八種臨床及IND階段候選藥物；\n3、預計約414.78百萬港元（相當于所得款項凈額的20%）將用于為研發管線中 其余五種候選藥物以及研發和尋求新候選藥物的許可提供資金；\n4、預計約207.39百萬港元（相當于所得款項凈額的10%）將用作營運資金及其 他一般公司用途。","shares":500,"leadagent":"高盛(亞洲)有限責任公司,摩根士丹利亞洲有限公司,瑞士銀行香港分行,招商證券(香港)有限公司","bookrunners":"高盛(亞洲)有限責任公司,摩根士丹利亞洲有限公司,瑞士銀行香港分行,招商證券(香港)有限公司","coordinator":"高盛(亞洲)有限責任公司,摩根士丹利亞洲有限公司,瑞士銀行香港分行,招商證券(香港)有限公司","firstDayOpen":"13.32","IsEiio":0,"Interestdays":6,"PENote":"按經審核的最近年度公司股東應占溢利和發行后總股本計算；發行價未確定時，按招股價中間價計算；發行價確定后，按招股定價計算。","OverAllotment":"有","StabilizingManager":"高盛(亞洲)有限責任公司","code":"E02616","name":"基石藥業－Ｂ","fullname":"基石藥業"},"institutioninfo":{"principaloffice":"中國上海市浦東新區張衡路1000號25號樓","registrars":"香港中央證券登記有限公司","registrarstel":"(852)2862 8628","chairman":"江寧軍","secretary":"何寧,李亮賢","telephone":"(86512)8718 6550","substantialshareholders":"WuXi Healthcare Ventures(29.76%),Graceful Beauty Limited(14.93%),正則原石(13.86%)","principalactivities":"公司為一間臨床階段生物制藥公司，專注于開發及商業化創新腫瘤免疫治療及分子靶向藥物，以滿足癌癥治療的殷切醫療需求。","website":"www.cstonepharma.com"},"managerinfo":[{"managername":"江寧軍","post":"主席、首席執行官兼執行董事","rankno":1},{"managername":"李偉","post":"非執行董事","rankno":2},{"managername":"趙群","post":"非執行董事","rankno":3}],"investorinfo":[{"institutionname":"GIC Private Limited","shareholding":"26,156,000.0","percentage":14.03,"ReleaseDate":"2019-08-26 00:00:00","relatedparty":"","subsidiary":[],"InverstorType":"公司"},{"institutionname":"Boyu Capital Opportunities Master Fund","shareholding":"13,078,000.0","percentage":7.02,"ReleaseDate":"2019-08-26 00:00:00","relatedparty":"Boyu Capital Investment Management Co., Limited","subsidiary":["Boyu Capital Opportunities Master Fund"],"InverstorType":"基金"},{"institutionname":"Ishana Capital Limited","shareholding":"13,078,000.0","percentage":7.02,"ReleaseDate":"2019-08-26 00:00:00","relatedparty":"","subsidiary":[],"InverstorType":"公司"},{"institutionname":"Indus Capital Partners,LLC","shareholding":"9,808,500.0","percentage":5.26,"ReleaseDate":"2019-08-26 00:00:00","relatedparty":"","subsidiary":[],"InverstorType":"公司"}],"TotalShareholdingPercentage":33.33},"result":1,"Version":"4.5.190802.46408","ElapsedMilliseconds":510}